Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) saw a significant drop in short interest in March. As of March 31st, there was short interest totalling 104,400 shares, a drop of 17.9% from the March 15th total of 127,100 shares. Based on an average daily trading volume, of 129,800 shares, the short-interest ratio is presently 0.8 days. Approximately 0.6% of the shares of the stock are sold short.

Hedge Funds Weigh In On Enlivex Therapeutics

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of Enlivex Therapeutics in the 4th quarter worth approximately $742,000. Renaissance Technologies LLC lifted its stake in Enlivex Therapeutics by 112.6% during the fourth quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock worth $186,000 after purchasing an additional 84,203 shares during the last quarter. Finally, Two Sigma Securities LLC acquired a new position in Enlivex Therapeutics in the fourth quarter worth $26,000. 1.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ENLV. D. Boral Capital reissued a “buy” rating and issued a $13.00 price target on shares of Enlivex Therapeutics in a research note on Monday. HC Wainwright increased their price target on Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a report on Monday, March 24th.

Enlivex Therapeutics Stock Performance

Shares of NASDAQ:ENLV traded up $0.02 during trading on Monday, hitting $0.88. The company’s stock had a trading volume of 44,235 shares, compared to its average volume of 131,558. Enlivex Therapeutics has a fifty-two week low of $0.81 and a fifty-two week high of $1.84. The stock’s 50-day moving average price is $1.02 and its two-hundred day moving average price is $1.16. The company has a market capitalization of $18.84 million, a PE ratio of -0.90 and a beta of 0.85.

Enlivex Therapeutics (NASDAQ:ENLV) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07). On average, equities analysts predict that Enlivex Therapeutics will post -0.7 earnings per share for the current fiscal year.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.